Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). J of Skin [Internet]. 2020 Oct. 27 [cited 2025 Apr. 4];4(6):s80. Available from: https://skin.dermsquared.com/skin/article/view/1113